Business Wire

INSTITUTO-COORDENADAS

13.10.2020 12:46:08 CEST | Business Wire | Press release

Share
INSTITUTO COORDENADAS: “An Analysis Group That Looks at the Options for Avoiding Global Collapse”

Barcelona’s efforts to become a safe destination for tourists have meant that, of all of Europe’s main tourism destinations, the city and its surrounding areas have been ranked as one of most committed to health safety matters. Monitoring and advice, alongside the involvement of the tourism sector’s main actors, have provided Barcelona with international acknowledgment that will benefit the sector’s recovery. Those are the main conclusions of an ongoing study by Institute Coordenadas into the impact of Covid-19 on the tourism industry.

One of the key indicators that place Barcelona at the forefront for safe spaces internationally is the backing for the city from the World Travel and Tourism Council (WTTC), which has launched a global quality stamp for tourist destinations that provided the strongest guarantees that their public spaces are Covid-secure. Barcelona is a member of the elite group of major European cities that safely welcome a high number of tourists. As such, the city is striving to provide the safest conditions for visitors, around 28 million of whom come to the Catalan capital every year, joining its population of just over 1.6 million. Seville was also acknowledged by the WTTC, along with other destinations in Portugal, Saudi Arabia and Cancun, Mexico.

Barcelona’s seventh position (and the title of top-ranked Spanish city) in the Saffron City Brand Barometer 2020 of the cities with the strongest tourism brands is also a key factor. Similarly, the Global Safe Site certification from Bureau Veritas highlights strict compliance with hygiene and safety measures in Barcelona, which was also the first Spanish city to be awarded the distinction. Key tourist infrastructure such as Park Güell, the city’s zoo and the Tibidabo amusement park have all been awarded the Safe Tourism Certified distinction by the Institute for Spanish Tourism Quality (ICTE), which marks the implementation of a specific Covid-19 risk prevention system. Furthermore, Barcelona has been Biosphere-certified since 2011 as an urban destination committed to sustainability.

The website promoted by Barcelona City Council as part of the Barcelona Safe City/Safe Visit initiative is a key element in the process of getting the city moving again post-Covid. The portal can be used by companies and professionals to check the information related to their respective fields and for obtaining a personalised report featuring all the necessary elements to ensure protocols adapt to maximum safety requirements.

The involvement of actors from different municipal levels has been one of the factors that has allowed Barcelona to compete to become a safer city in terms of health. The Safe City initiative included an interdisciplinary working group with members from the Catalan Directorate of Tourism, the Public Health Agency of Catalonia, the Municipal Civil Defence Service, the Guàrdia Urbana municipal police force, BCNecologia/Barcelona Urban Ecology Agency, the city’s Department of Commerce, its Culture Institute and the Barcelona Sports Institute, municipal company B:SM, trade fair organisation Fira de Barcelona, the Turisme de Barcelona Consortium and ISGlobal.

Another aspect that will improve safety features for tourists in Barcelona is the introduction of the app currently being put together by the Turisme de Barcelona Consortium and Barcelona City Council. The app will allow users to check on health recommendations and the situation at visitor locations, so as to avoid crowds and queueing. The app’s initial launch phase will feature opening times and entry points for the most popular tourist destinations, along with guidance for health and mobility. Plans for the second phase include real-time information and the option of booking ahead to ensure safer management of tourist activities. The app is being developed by Eurecat Technology Centre in collaboration with the Mobile World Capital Barcelona Foundation and Barcelona Tech City.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release

ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye